Cancer cells may have found an unexpected Achilles' heel in their own evolutionary baggage. New research reveals that blocking a protein called menin not only fights acute myeloid leukemia directly but unleashes a surprising immune cascade that makes cancer cells more visible and vulnerable to therapeutic T-cell attacks.
The investigation focused on menin inhibitors in AML cases involving KMT2A gene rearrangements, which typically resist bone marrow transplant treatments. Beyond the known anti-cancer effects, menin blockade triggered expression of dormant human endogenous retroviruses embedded in cancer cell DNA—viral remnants from ancient infections now repurposed as an anti-cancer weapon. This viral awakening activated interferon pathways, dramatically increasing MHC-II protein display on cancer cell surfaces, essentially forcing them to wave red flags for immune recognition. Simultaneously, menin inhibition directly energized donor T-cells, boosting production of tumor necrosis factor-alpha, interferon-gamma, and cytotoxic molecules like perforin and granzyme.
This dual mechanism represents a paradigm shift in understanding how epigenetic drugs might enhance immunotherapy. Most current approaches focus on either direct cancer killing or immune activation separately. The endogenous retrovirus connection is particularly intriguing—these 'fossil viruses' comprise roughly 8% of human DNA, yet their therapeutic potential remains largely unexplored. While promising, the findings come primarily from mouse models and cell cultures. The critical question is whether menin inhibitors can achieve similar immune enhancement in human patients without triggering autoimmune complications, given the broad activation of viral elements and interferon responses.